AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
19 C
New York
Thursday, October 22, 2026

Tag: therapies

newsFORsourcecompanycontentinformation1releasesmarket

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Independence Blue Cross and Children’s Hospital of Philadelphia sign new agreement that reflects their joint commitment to children’s health in the region

PHILADELPHIA, June 17, 2025 /PRNewswire/ -- Independence Blue Cross (IBX) and Children's Hospital of Philadelphia (CHOP) have signed a new, multi-year agreement, which will be...

Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs

The Catalyst Award will expedite the hunt for a validated test-to-treat model for ME/CFS, a disease for which there is currently no FDA-approved treatment. LOS...

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

CHICAGO, June 17, 2025 /PRNewswire/ -- The Global Medical Biomimetics Market is projected to be valued at USD 35.68 billion in 2024 and reach USD 55.36 billion by 2030, growing...

Lung Cancer Research Foundation Announces Request for Proposals Focused on Curing EGFR Mutant Lung Cancers

New Team Science Award is $1.5 million Over Three Years NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces today...

BioRestorative Announces Share Repurchase Program

MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.

Lung Cancer Research Foundation Announces New Research Collaboration with Boehringer Ingelheim

$2.25 Million Research Collaboration Focused on Understanding and Treating Lung Cancers Harboring HER2 Mutations; call for Requests for Proposals NEW YORK, June 17, 2025 /PRNewswire/...

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -

Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the...

TEL AVIV, Israel, June 17, 2025 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its...

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology

Exobiosphere and Space Cargo Unlimited Unite for High-Throughput Biotech in Space

Paris Air Show, Le Bourget – June 16, 2025 – Booth B46 (Alliance NewSpace Pavilion, Paris Space Hub) PARIS, June 17, 2025 /PRNewswire/ -- Exobiosphere...

Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients

Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin.

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...

Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight

The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers